Li Zeng

CEO

Jing Medicine

Short Biography

Dr. Li ZENG joined Jing Medicine as Chief Executive Officer in November 2021, bringing with him a wealth of R&D and business operation experience in the pharmaceutical industry with a career spanning over 18 years. He has held drug R&D, portfolio and project management positions of increasing responsibilities in multinational companies such as Novartis and Eli Lilly as well as in traditional local pharma and biotech firms such as Luoxin Pharmaceutical, 4B Technologies and Harbour Biomed. 
Dr. Zeng received his bachelor’s degree in chemistry from Peking University and Ph.D. in Organic Chemistry from Stanford University. He conducted his postdoctoral research training in Chemical Biology at University of California, Berkeley.

Presentation Topic: HJ-004: An Efficacious, Selective and Orally Bioavailable pan EGFRm-PROTAC to Treat Non-Small-Cell Lung Cancer